Let's talk about Money & Finance @EY24 April 2023
Let's talk about Money & Finance @EY
24 April 2023
Shelley Margetson | Managing Partner, V-Bio Ventures
Shelley Margetson | Managing Partner, V-Bio Ventures
Shelley Margetson joined V-Bio ventures as managing partner in December 2020. Prior to joining V-Bio, Shelley spent over 20 years in executive roles in both finance and business, in multiple European biotechnology companies. As CFO of Merus (MRUS) she managed the Initial Public Offering on the Nasdaq in May 2016 and as CEO of Gadeta she closed a ‘build to buy’ deal with Kite/Gilead. Shelley has managed funding rounds, business exits and negotiated multiple international business transactions.
V-Bio Ventures
V-Bio Ventures is a life sciences Venture Capital fund that helps transform scientific innovation into products that positively impact people’s lives. We invest in private companies with differentiated technology addressing unmet needs. We look for innovative and transformational technologies with high societal and/or environmental impact potential, in line with the U.N. Sustainable Development Goals.We focus on therapeutics, diagnostics supporting medical therapies, and sustainable agriculture.
V-Bio Ventures is a life sciences Venture Capital fund that helps transform scientific innovation into products that positively impact people’s lives. We invest in private companies with differentiated technology addressing unmet needs. We look for innovative and transformational technologies with high societal and/or environmental impact potential, in line with the U.N. Sustainable Development Goals.We focus on therapeutics, diagnostics supporting medical therapies, and sustainable agriculture.
| Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
| Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | | |
© Copyright 2020 by Hyphen Projects